Metabolic Peptides

5-Amino-1-Methylquinolinium · NNMT Inhibitor

A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.

NNC0487-0111 · Oral Amycretin · Subcutaneous Amycretin

A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.

Anti-Obesity Drug 9604 · Tyr-hGH Fragment 177-191 · hGH Fragment 176-191

A modified fragment of human growth hormone (amino acids 176-191 with N-terminal tyrosine) studied for fat loss. Clinical development discontinued after Phase 2b/3 trials failed to show efficacy in 536 subjects. Now prohibited by WADA and excluded from FDA compounding.

AM833 · NN9838

A long-acting amylin analog developed by Novo Nordisk for weight management. Studied in Phase 3 trials as CagriSema (combination with semaglutide). The Phase 3 REDEFINE 1 trial showed -20.4% weight loss with cagrilintide-semaglutide versus -3.0% with placebo at 68 weeks.

Cagrilintide-Semaglutide · NNC0174-0833

A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) for chronic weight management. Phase 3 REDEFINE trials demonstrate 20-23% weight loss at 68 weeks. NDA submitted to FDA December 2025. First GLP-1/amylin combination therapy.

RG-6912

A dual GLP-1/GIP receptor agonist (INN enicepatide; also RO7795068) acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. The published Phase 1 trial (NCT04838405) showed 4.7-8.0% mean weight loss vs 0.5% placebo over 4 weeks; a more widely reported ~18.8% placebo-adjusted figure at 24 weeks comes from an unpublished Phase 1 extension reported via press release. Phase 2 obesity and T2D trials are completed or ongoing and Phase 3 began in 2026, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.

XW003 · Sciwind GLP-1

A long-acting GLP-1 receptor agonist developed by Sciwind Biosciences. A Phase 3 obesity trial showed 13.2% weight loss at 40 weeks with once-weekly dosing. Primarily targeting China and Asian markets with potential for global expansion.

Victoza · Saxenda · NN2211

The first long-acting GLP-1 receptor agonist, FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014). Pioneered the therapeutic class with proven cardiovascular benefits in the landmark LEADER trial.

AMG 133 · maridebart cafraglutide

A bispecific peptide-antibody conjugate combining GLP-1 receptor agonism with GIP receptor antagonism. Unique mechanism opposite to tirzepatide. The published Phase 2 trial (NCT05669599) showed up to ~16% weight loss at 52 weeks with once-monthly dosing. MARITIME Phase 3 program ongoing.

IBI362 · LY3305677 · Xinermei

A dual GLP-1 and glucagon receptor agonist developed by Innovent/Eli Lilly. NMPA approved in China (2025) for obesity. The GLORY-1 trial showed 14.0% weight loss at 48 weeks with the 6mg dose. The DREAMS-3 head-to-head trial vs semaglutide for combined diabetes + obesity outcomes is ongoing, with results not yet published.

LY3502970 · OWL833

The first oral small-molecule (non-peptide) GLP-1 receptor agonist. NDA submitted to FDA. ATTAIN trials showed 11.2% weight loss at 72 weeks. No food/water restrictions unlike oral semaglutide. Phase 3 data in 9,000+ patients.

ALT-801 · GLP-1/Glucagon Dual Agonist

A dual GLP-1/glucagon receptor agonist developed by Altimmune showing 15.6% weight loss at 48 weeks with a high proportion of fat mass lost. Phase 2 trials completed for obesity (MOMENTUM) and MASH (IMPACT), with the IMPACT trial meeting its MASH-resolution primary endpoint (52% at 1.8 mg vs 20% placebo at 24 weeks). FDA Fast Track designation for MASH.

Pfizer GLP-1 · Monthly GLP-1

Pfizer's once-monthly GLP-1 receptor agonist peptide (Metsera MET097 lineage). The once-monthly Phase 2b (SOLIS-1, NCT07575932) is recruiting with no reported results yet, and the molecule has no published efficacy data. A Phase 3 program (VESPER-4/5/6) is enrolling, positioning it as a potential long-acting alternative to weekly GLP-1 therapies.

LY3437943 · GGG Triple Agonist

A triple GIP/GLP-1/glucagon receptor agonist. Phase 2 data show 24.2% weight loss at 48 weeks (12mg), the largest reduction reported for an incretin-based therapy. The Phase 3 TRIUMPH registrational program is ongoing.

Ozempic · Wegovy · Rybelsus +1

A GLP-1 receptor agonist FDA-approved for type 2 diabetes, obesity, cardiovascular risk reduction, and MASH. Among the most extensively studied peptides with robust Phase 3 data demonstrating significant metabolic, cardiovascular, renal, and hepatic benefits.

ERR agonist 332 · Exercise mimetic compound

A small molecule ERR (Estrogen-Related Receptor) agonist developed at Saint Louis University. Preclinical studies suggest exercise-mimetic properties, but no human data exists. Represents early-stage research into pharmacologically activating exercise pathways.

BI 456906 · BI-456906 · ZP6590

A dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim/Zealand Pharma, currently in Phase 3 trials for obesity and MASH. Phase 2 data show up to 14.9% weight loss and up to 62% MASH improvement, with unique liver-targeting benefits from glucagon receptor agonism.

LY3298176 · Mounjaro · Zepbound

A dual GIP/GLP-1 receptor agonist approved globally for type 2 diabetes (Mounjaro), weight management (Zepbound), and obstructive sleep apnea. Extensive clinical trial data from 30+ countries demonstrates significant effects on glycemic control, body weight, and cardiovascular outcomes.

Viking 2735

A dual GLP-1/GIP receptor agonist from Viking Therapeutics with both subcutaneous and oral formulations. Phase 2 VENTURE trial showed 14.7% weight loss at 13 weeks (SC) and 12.2% (oral). Phase 3 VANQUISH-1 enrolled 4,500 patients.